Informed Consent
Written informed consent was obtained from all individual participants
included in the study.
Author contributions
F.S. and B.S. designed the research; F.S. analysed the data and B.S.
checked the analysis code; F.S. drafted the manuscript and B.S. revised
it; T.N.M.N., and H.B. contributed important intellectual content to the
discussion. All authors were involved in the interpretation and
discussion of results.
Data Availability Statement
The data that support the findings of this study are available from the
UK Biobank. Restrictions apply to the availability of these data, which
were used under license for this study. Data and analysis code (SAS) are
available [https://www.ukbiobank.ac.uk/] with the permission of UK
Biobank after approval of a research proposal and payment of a
fee.
ORCID
Fatemeh Safizadeh - None
Thi Ngoc Mai Nguyen - None
Hermann Brenner - None
Ben Schöttker - 0000-0002-1217-4521
References
1. Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition
by SARS-CoV-2. Nature. 2020;581(7807):221-224.
2. Kreutz R, Algharably EAE, Azizi M, et al. Hypertension, the
renin-angiotensin system, and the risk of lower respiratory tract
infections and lung injury: implications for COVID-19. Cardiovasc
Res. 2020;116(10):1688-1699.
3. Del Turco S, Vianello A, Ragusa R, Caselli C, Basta G. COVID-19 and
cardiovascular consequences: Is the endothelial dysfunction the hardest
challenge? Thromb Res. 2020;196:143-151.
4. Mascolo A, Scavone C, Rafaniello C, et al. The Role of
Renin-Angiotensin-Aldosterone System in the Heart and Lung: Focus on
COVID-19. Front Pharmacol. 2021;12:667254.
5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected
with 2019 novel coronavirus in Wuhan, China. The Lancet.2020;395(10223):497-506.
6. Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers may increase the risk of severe COVID-19.J Travel Med. 2020;27(3).
7. Ferrario CM, Jessup J, Chappell MC, et al. Effect of
angiotensin-converting enzyme inhibition and angiotensin II receptor
blockers on cardiac angiotensin-converting enzyme 2. Circulation.2005;111(20):2605-2610.
8. Speth RC. Keep taking your ACE inhibitors and ARBs during the COVID
19 pandemic. J Travel Med. 2020;27(3).
9. Tomasoni D, Italia L, Adamo M, et al. COVID-19 and heart failure:
from infection to inflammation and angiotensin II stimulation. Searching
for evidence from a new disease. Eur J Heart Fail.2020;22(6):957-966.
10. Reynolds HR, Adhikari S, Pulgarin C, et al.
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.N Engl J Med. 2020;382(25):2441-2448.
11. Ferrari F, Martins VM, Fuchs FD, Stein R.
Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review.Clinics (Sao Paulo). 2021;76:e2342.
12. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G.
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.N Engl J Med. 2020;382(25):2431-2440.
13. Simko F, Hrenak J, Adamcova M, Paulis L.
Renin-Angiotensin-Aldosterone System: Friend or Foe-The Matter of
Balance. Insight on History, Therapeutic Implications and COVID-19
Interactions. Int J Mol Sci. 2021;22(6).
14. Alves M, Fernandes MA, Bahat G, et al. Protecting older patients
with cardiovascular diseases from COVID-19 complications using current
medications. Eur Geriatr Med. 2021.
15. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access
resource for identifying the causes of a wide range of complex diseases
of middle and old age. PLoS Med. 2015;12(3):e1001779.
16. UK Biobank. Facilitating COVID-19 research.
https://www.ukbiobank.ac.uk/enable-your-research/about-our-data/covid-19-data.
Published 2021. Updated 11/12/2020. Accessed 07/07/2021, 2021.
17. Khanji MY, Aung N, Chahal CAA, Petersen SE. COVID-19 and the UK
Biobank-Opportunities and Challenges for Research and Collaboration With
Other Large Population Studies. Front Cardiovasc Med. 2020;7:156.
18. Public Health England. Coronavirus (COVID-19) in the UK
https://coronavirus.data.gov.uk/details/vaccinations. Published
2021. Updated 07/07/2021. Accessed 07/07/2021, 2021.
19. Townsend P. Deprivation. Journal of Social Policy.1987;16(2):125-146.
20. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate
glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
21. Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19
disease with ACE inhibitors and angiotensin receptor blockers: cohort
study including 8.3 million people. Heart.2020;106(19):1503-1511.
22. Savarese G, Benson L, Sundstrom J, Lund LH. Association between
renin-angiotensin-aldosterone system inhibitor use and COVID-19
hospitalization and death: a 1.4 million patient nationwide registry
analysis. Eur J Heart Fail. 2021;23(3):476-485.
23. Kaur U, Chakrabarti SS, Patel TK. Renin-angiotensin-aldosterone
system blockers and region-specific variations in COVID-19 outcomes:
findings from a systematic review and meta-analysis. Ther Adv Drug
Saf. 2021;12:20420986211011345.
24. Ren L, Yu S, Xu W, Overton JL, Chiamvimonvat N, Thai PN. Lack of
association of antihypertensive drugs with the risk and severity of
COVID-19: A meta-analysis. J Cardiol. 2021;77(5):482-491.
25. Caldeira D, Alves M, Gouveia EMR, et al. Angiotensin-converting
enzyme inhibitors and angiotensin-receptor blockers and the risk of
COVID-19 infection or severe disease: Systematic review and
meta-analysis. Int J Cardiol Heart Vasc. 2020;31:100627.
26. Gault N, Esposito-Farese M, Revest M, et al. Chronic use of
renin-angiotensin-aldosterone system blockers and mortality in COVID-19:
A multicenter prospective cohort and literature review. Fundam
Clin Pharmacol. 2021.
27. Pirola CJ, Sookoian S. Estimation of
Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19
outcome: A Meta-analysis. J Infect. 2020;81(2):276-281.
28. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA,
Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients
with Covid-19. N Engl J Med. 2020;382(17):1653-1659.
29. Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers
and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon
Renin-Angiotensin System Blockers. Hypertension.2020;75(6):1382-1385.
30. Lopes RD, Macedo AVS, de Barros ESPGM, et al. Effect of
Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and
Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital
in Patients Admitted With COVID-19: A Randomized Clinical Trial.JAMA. 2021;325(3):254-264.
31. Puskarich MA, Cummins NW, Ingraham NE, et al. A multi-center phase
II randomized clinical trial of losartan on symptomatic outpatients with
COVID-19. EClinicalMedicine. 2021;37:100957.
Table
1. Characteristics of the study population of patients with
hypertension, overall Covid-19, and hospitalized Covid-19 patient
subpopulations